{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:22:18Z","timestamp":1793762538718,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-020-00399-8","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T08:05:45Z","timestamp":1610525145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-7897","authenticated-orcid":false,"given":"Manette A. W.","family":"Dinnessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardus F. M.","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-6716","authenticated-orcid":false,"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"399_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","volume":"29","author":"HR Junlen","year":"2015","unstructured":"Junlen, H. R. et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia 29, 668\u2013676 (2015).","journal-title":"Leukemia"},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant, M. et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 15, 931\u2013942 (2014).","journal-title":"Lancet Oncol."},{"key":"399_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3324\/haematol.2012.081885","volume":"99","author":"SAM van de Schans","year":"2014","unstructured":"van de Schans, S. A. M., van Steenbergen, L. N., Coebergh, J. W. W., Janssen-Heijnen, M. L. G. & van Spronsen, D. J. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica 99, 339\u2013345 (2014).","journal-title":"Haematologica"},{"key":"399_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3109\/10428194.2015.1102246","volume":"57","author":"Y Migdady","year":"2016","unstructured":"Migdady, Y., Salhab, M., Dang, N. H., Markham, M. J. & Olszewski, A. J. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. Leuk. Lymphoma 57, 676\u2013684 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"399_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ije\/22.3.369","volume":"22","author":"LJ Schouten","year":"1993","unstructured":"Schouten, L. J., Hoppener, P., van den Brandt, P. A., Knottnerus, J. A. & Jager, J. J. Completeness of cancer registration in Limburg, The Netherlands. Int. J. Epidemiol. 22, 369\u2013376 (1993).","journal-title":"Int. J. Epidemiol."},{"key":"399_CR6","unstructured":"Fritz, A. P. & Jack, C. A. International Classification of Diseases for Oncology 3 edn (World Health Organisation, Geneva, 2000)."},{"key":"399_CR7","first-page":"101","volume":"6","author":"F Ederer","year":"1961","unstructured":"Ederer, F., Axtell, L. M. & Cutler, S. J. The relative survival rate: a statistical methodology. Natl Cancer Inst. Monogr. 6, 101\u2013121 (1961).","journal-title":"Natl Cancer Inst. Monogr."},{"key":"399_CR8","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.ejca.2004.07.022","volume":"40","author":"H Brenner","year":"2004","unstructured":"Brenner, H. & Rachet, B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur. J. Cancer 40, 2494\u20132501 (2004).","journal-title":"Eur. J. Cancer"},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/10428194.2017.1349905","volume":"59","author":"EM Ammann","year":"2018","unstructured":"Ammann, E. M. et al. Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) based on treatment-free interval length. Leuk. Lymphoma 59, 643\u2013649 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"399_CR10","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/cncr.31529","volume":"124","author":"C Anderson","year":"2018","unstructured":"Anderson, C., Smitherman, A. B. & Nichols, H. B. Conditional relative survival among long-term survivors of adolescent and young adult cancers. Cancer 124, 3037\u20133043 (2018).","journal-title":"Cancer"},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl, B. S. et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J. Clin. Oncol. 32, 3096\u20133102 (2014).","journal-title":"J. Clin. Oncol."},{"key":"399_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna, K. M. et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 15, 424\u2013435 (2014).","journal-title":"Lancet Oncol."},{"key":"399_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny, P. et al. Follicular lymphoma international prognostic index. Blood 104, 1258\u20131265 (2004).","journal-title":"Blood"},{"key":"399_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjh.13399","volume":"170","author":"C Nabhan","year":"2015","unstructured":"Nabhan, C. et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma\u2010related mortality in elderly follicular lymphoma in the United States. Br. J. Haematol. 170, 85\u201395 (2015).","journal-title":"Br. J. Haematol."},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.15513","volume":"183","author":"E Gyan","year":"2018","unstructured":"Gyan, E. et al. Bendamustine and rituximab in elderly patients with low\u2010tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. Br. J. Haematol. 183, 76\u201386 (2018).","journal-title":"Br. J. Haematol."},{"key":"399_CR17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn, I. W. et al. First-line treatment of patients with indolent Non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year follow-up study. J. Clin. Oncol. 37, 984\u2013991 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00399-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:39:02Z","timestamp":1669909142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00399-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00399-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}